{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:58:44Z","timestamp":1777481924900,"version":"3.51.4"},"reference-count":25,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"published-print":{"date-parts":[[2014,3]]},"abstract":"<jats:p>\n                    Outpatient daily intravenous infusions of interleukin-2 (IL-2) have been developed to maintain anticancer activity and decrease toxicity of this agent against kidney cancer. Lymphokine activated killer cell (LAK) numbers are increased with these IL-2 schedules. Famotidine may enhance the LAK activity by increasing IL-2 internalization by the IL-2 receptor on lymphocytes. Fifteen patients with metastatic clear cell kidney cancer received IL-2 18 million IU\/M\n                    <jats:sup>2<\/jats:sup>\n                    intravenously over 15\u201330 minutes preceded by famotidine 20\u2009mg IV daily for 3 days for 6 consecutive weeks as outpatients. Cycles were repeated every 8 weeks. Patient characteristics were seven males\/eight females, median age 59 (range: 28\u201370), median Eastern Cooperative Oncology Group (ECOG) performance status-1; common metastatic sites were lungs (14), lymph nodes (9), liver (4), bone (4), and pancreas (4). Prior systemic therapies were oral tyrosine kinase inhibitor (8), IL-2 (6), and mTor inhibitor (2). Most common toxicities were rigors, arthralgia\/myalgia, nausea\/emesis, fever, and hypotension. All episodes of hypotension were reversible with intravenous fluid. No patients required hospitalization due to toxicity. One complete response (7%) and four partial responses (26%) were seen (total response rate=33%; 95% confidence interval: 15%\u201359%). Responses occurred in the lungs, liver, lymph nodes, and bone. Outpatient intravenous IL-2 with famotidine has activity in metastatic clear cell kidney cancer.\n                  <\/jats:p>","DOI":"10.1089\/cbr.2013.1555","type":"journal-article","created":{"date-parts":[[2013,11,19]],"date-time":"2013-11-19T10:06:35Z","timestamp":1384855595000},"page":"58-61","source":"Crossref","is-referenced-by-count":0,"title":["Activity of Outpatient Intravenous Interleukin-2 and Famotidine in Metastatic Clear Cell Kidney Cancer"],"prefix":"10.1177","volume":"29","author":[{"suffix":"Jr.","given":"Walter D.Y.","family":"Quan","sequence":"first","affiliation":[{"name":"Western Regional Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francine Marie","family":"Quan","sequence":"additional","affiliation":[{"name":"Loma Linda University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2014,3,1]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.155.6.1823"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.140.4.1335"},{"key":"e_1_3_2_4_2","first-page":"3680","article-title":"Lymphokine-activated killer activity induced by in vivo Interleukin-2 therapy: Predominant role for lymphocytes with increased expression of CD2 and Leu19 antigens but negative expression of CD16 antigens","volume":"49","author":"Weil-Hillman G","year":"1989","unstructured":"Weil-Hillman G, , Fisch P, , Prieve AF, et al. Lymphokine-activated killer activity induced by in vivo Interleukin-2 therapy: Predominant role for lymphocytes with increased expression of CD2 and Leu19 antigens but negative expression of CD16 antigens. Cancer Res, 1989; 49:3680.","journal-title":"Cancer Res"},{"issue":"1","key":"e_1_3_2_5_2","first-page":"S55","article-title":"Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma","volume":"6","author":"Fisher RI","year":"2000","unstructured":"Fisher RI, , Rosenberg SA, , Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am, 2000; 6(suppl 1):S55.","journal-title":"Cancer J Sci Am"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.4.486"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.4.694"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-200305000-00012"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0192-0561(92)90107-V"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2012.1239"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/028418602760169415"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2010.0879"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00873233"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/82.2.143"},{"key":"e_1_3_2_16_2","first-page":"641","article-title":"High dose intensity pulse Interleukin-2 with famotidine has activity in metastatic melanoma","volume":"23","author":"Quan WDY","year":"2008","unstructured":"Quan WDYJr, , Walker PR, , Picton M, et al. High dose intensity pulse Interleukin-2 with famotidine has activity in metastatic melanoma. Cancer Biother Radiopharm, 2008; 23:641.","journal-title":"Cancer Biother Radiopharm"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2008.0564"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2009.0737"},{"key":"e_1_3_2_19_2","first-page":"1686","article-title":"Generation of human lymphokine-activated killer cells following brief exposure to high dose interleukin-2","volume":"50","author":"Horton SA","year":"1990","unstructured":"Horton SA, , Oldham RK, , Yannelli JR. Generation of human lymphokine-activated killer cells following brief exposure to high dose interleukin-2. Cancer Res, 1990; 50:1686.","journal-title":"Cancer Res"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1994.03510360033032"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.8.622"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.7.1233"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-108-4-518"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.7.1138"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.4.641"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.4.477"}],"container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cbr.2013.1555","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cbr.2013.1555","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cbr.2013.1555","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:14:07Z","timestamp":1777385647000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cbr.2013.1555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["10.1089\/cbr.2013.1555"],"URL":"https:\/\/doi.org\/10.1089\/cbr.2013.1555","relation":{},"ISSN":["1084-9785","1557-8852"],"issn-type":[{"value":"1084-9785","type":"print"},{"value":"1557-8852","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}